5-year, long-term safety from CLL/SLL studies1,2*

In pooled data from multiple open-label rollover and follow-up studies in both treatment-naïve and relapsed/refractory CLL/SLL patients (N=808), the median treatment duration was 51 months (range 0.2 to 98 months). Due to types of events collected and less frequent clinic visits, limited data were collected from 1 follow-up study.

Most common treatment-emergent ARs (any grade) in ≥20% of patients with CLL/SLL (N=808)2